Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks

BACKGROUND: We assessed the efficacy and safety of dolutegravir/lamivudine (DTG/3TC) in a US test-and-treat setting at a secondary 48-week time point of the multicenter, single-arm, phase IIIb STAT study. METHODS: Participants were eligible adults newly diagnosed with human immunodeficiency virus (H...

Descripción completa

Detalles Bibliográficos
Autores principales: Rolle, Charlotte-Paige, Berhe, Mezgebe, Singh, Tulika, Ortiz, Roberto, Wurapa, Anson, Ramgopal, Moti, Jayaweera, Dushyantha T, Leone, Peter A, Matthews, Jessica E, Cupo, Michael, Underwood, Mark R, Angelis, Konstantinos, Wynne, Brian R, Merrill, Deanna, Nguyen, Christopher, van Wyk, Jean, Zolopa, Andrew R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034754/
https://www.ncbi.nlm.nih.gov/pubmed/36968959
http://dx.doi.org/10.1093/ofid/ofad101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034754/
https://www.ncbi.nlm.nih.gov/pubmed/36968959
http://dx.doi.org/10.1093/ofid/ofad101

Ejemplares similares